2.3
2022

Asthma and COVID-19 pandemic: focus on the eosinophil count and ACE2 expression

Show more: Authors information and Publication history
Authors Information

1Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Allergy and Clinical Immunology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran

History

Published: 09 September 2021
Accepted: 06 September 2021
Received: 01 November 2021

SUMMARY

Currently, the world is engaged with a coronavirus disease 2019 (COVID-19) caused by acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection. The Center for Disease Control and Prevention (CDC) has proposed moderate to severe asthma as a risk factor for COVID-19 susceptibility and severity. However, current evidences have not identified asthma in the top 10 comorbidities associated with COVID-19 fatalities. It raises the question that why patients with different type of asthma are not more vulnerable to SARS-CoV-2 infection like other respiratory infection. Increased number of eosinophils and elevated angiotensin-converting enzyme 2 (ACE2) expressions in asthma are supposed as two mechanisms which associated with decreased COVID-19 susceptibility in asthmatics. Some studies have been performed to evaluate two mentioned factors in asthmatic patients compared with healthy individuals. Herein, we address these mechanisms and investigate whether ACE2 and eosinophil could protect asthmatic patients against SARS-CoV-2 infection.

KEY WORDS
Asthma; SARS-CoV-2; COVID-19; ACE2; eosinophil.

Table of Content: Vol. 54 (No. 6) 2022 November

European Annals of Allergy and Clinical Immunology ISSN 1764-1489 | © 2024